Evidence map›Paper›PMID 25148251›Full record

ArticlePloS one2014

Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1*/DQB1* in malaria exposed individuals from the Brazilian Amazon.

Amanda Ribeiro Ferreira, Balwan Singh, Monica Cabrera-Mora, Alana Cristina Magri De Souza, Maria Teresa Queiroz Marques, Luis Cristovão Sobrino Porto, Fatima Santos, Dalma Maria Banic, J Mauricio Calvo-Calle, Joseli Oliveira-Ferreira and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Amanda Ribeiro FerreiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Balwan SinghEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Monica Cabrera-MoraEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America.
Alana Cristina Magri De SouzaLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Maria Teresa Queiroz MarquesHistocompatibility and Cryopreservation Laboratory, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Luis Cristovão Sobrino PortoHistocompatibility and Cryopreservation Laboratory, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Fatima SantosNational Health Foundation, Department of Entomology, Central Laboratory, Porto Velho, RO, Brazil.
Dalma Maria BanicLaboratory for Simuliidae and Onchocerciasis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
J Mauricio Calvo-CalleDepartment of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
Joseli Oliveira-FerreiraLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Alberto MorenoEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, United States of America; Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia, United States of America.
Josué Da Costa Lima-JuniorLaboratory of Immunoparasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz · BREmory University · USUniversidade do Estado do Rio de Janeiro · BRHealth Foundation · GBUniversity of Massachusetts Chan Medical School · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 1985 to 2011
$114.0M
Modular Chimeric Vaccines tailored for malaria parasitesR01AI064766 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2006 to 2010
$2.0M
Coadministration of capsid modified adenovirus for malaria vaccine developmentR21AI095718 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2012 to 2013
$490k
Chimeric hybrid transmission blocking vaccine for malariaR21AI094402 · NIAID · EMORY UNIVERSITY · PI MORENO, ALBERTO · 2012 to 2013
$484k
NCRR NIH HHS P51 RR000165NCRR NIH HHS RR00165NIAID NIH HHS R01 AI064766NIAID NIH HHS R01-AI064766NIAID NIH HHS R21 AI094402NIAID NIH HHS R21AI094402-01NIAID NIH HHS R21 AI095718NIAID NIH HHS R21AI095718-01NIH HHS P51 OD011132PHS HHS U19-57319
6 · The paper itself

Abstract

The development of modular constructs that include antigenic regions targeted by protective immune responses is an attractive approach for subunit vaccine development. However, a main concern of using these vaccine platforms is how to preserve the antigenic identity of conformational B cell epitopes. In the present study we evaluated naturally acquired antibody responses to a chimeric protein engineered to contain a previously defined immunodominant domain of the Plasmodium vivax reticulocyte binding protein-1 located between amino acid positions K435-I777. The construct also includes three regions of the cognate protein (F571-D587, I1745-S1786 and L2235-E2263) predicted to contain MHC class II promiscuous T cell epitopes. Plasma samples from 253 naturally exposed individuals were tested against this chimeric protein named PvRMC-RBP1 and a control protein that includes the native sequence PvRBP123-751 in comparative experiments to study the frequency of total IgG and IgG subclass reactivity. HLA-DRB1 and HLA-DQB1 allelic groups were typed by PCR-SSO to evaluate the association between major HLA class II alleles and antibody responses. We found IgG antibodies that recognized the chimeric PvRMC-RBP1 and the PvRBP123-751 in 47.1% and 60% of the studied population, respectively. Moreover, the reactivity index against both proteins were comparable and associated with time of exposure (p<0.0001) and number of previous malaria episodes (p<0.005). IgG subclass profile showed a predominance of cytophilic IgG1 over other subclasses against both proteins tested. Collectively these studies suggest that the chimeric PvRMC-RBP1 protein retained antigenic determinants in the PvRBP1435-777 native sequence. Although 52.9% of the population did not present detectable titers of antibodies to PvRMC-RBP1, genetic restriction to this chimeric protein does not seem to occur, since no association was observed between the HLA-DRB1* or HLA-DQB1* alleles and the antibody responses. This experimental evidence strongly suggests that the identity of the conformational B cell epitopes is preserved in the chimeric protein.

Indexed as

AdolescentAdultAgedAged, 80 and overAmino Acid SequenceAnimalsBrazilCase-Control StudiesChildEpitopes, T-LymphocyteFemaleHLA-DQ beta-ChainsHLA-DRB1 ChainsHumansImmunoglobulin GMalaria VaccinesEpitopes, T-LymphocyteHLA-DQB1 antigenHLA-DQ beta-ChainsHLA-DRB1 ChainsImmunoglobulin GMalaria VaccinesMembrane ProteinsProtozoan ProteinsRecombinant Proteinsreticulocyte-binding protein, Plasmodium vivax

Identifiers

PMID25148251
PMCPMC4141821
OpenAlexW1986622669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.